Your browser doesn't support javascript.
loading
Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.
Legdeur, Nienke; Badissi, Maryam; Carter, Stephen F; de Crom, Sophie; van de Kreeke, Aleid; Vreeswijk, Ralph; Trappenburg, Marijke C; Oudega, Mardien L; Koek, Huiberdina L; van Campen, Jos P; Keijsers, Carolina J P W; Amadi, Chinenye; Hinz, Rainer; Gordon, Mark F; Novak, Gerald; Podhorna, Jana; Serné, Erik; Verbraak, Frank; Yaqub, Maqsood; Hillebrand, Arjan; Griffa, Alessandra; Pendleton, Neil; Kramer, Sophia E; Teunissen, Charlotte E; Lammertsma, Adriaan; Barkhof, Frederik; van Berckel, Bart N M; Scheltens, Philip; Muller, Majon; Maier, Andrea B; Herholz, Karl; Visser, Pieter Jelle.
Afiliação
  • Legdeur N; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, PO Box 7057, 1007, MB, Amsterdam, the Netherlands. n.legdeur@vumc.nl.
  • Badissi M; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, PO Box 7057, 1007, MB, Amsterdam, the Netherlands.
  • Carter SF; Wolfson Molecular Imaging Centre, Division of Neuroscience & Experimental Psychology, University of Manchester, Manchester, UK.
  • de Crom S; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, PO Box 7057, 1007, MB, Amsterdam, the Netherlands.
  • van de Kreeke A; Department of Ophthalmology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Vreeswijk R; Department of Geriatric Medicine, Spaarne Gasthuis, Haarlem, The Netherlands.
  • Trappenburg MC; Department of Internal Medicine, Amstelland Hospital, Amstelveen, The Netherlands.
  • Oudega ML; Department of Psychiatry, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Koek HL; Department of Geriatric Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van Campen JP; Department of Geriatric Medicine, MC Slotervaart Hospital, Amsterdam, The Netherlands.
  • Keijsers CJPW; Department of Geriatric Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
  • Amadi C; Wolfson Molecular Imaging Centre, Division of Neuroscience & Experimental Psychology, University of Manchester, Manchester, UK.
  • Hinz R; Wolfson Molecular Imaging Centre, Division of Neuroscience & Experimental Psychology, University of Manchester, Manchester, UK.
  • Gordon MF; Teva Pharmaceuticals, North Wales, Pennsylvania, USA.
  • Novak G; Janssen Pharmaceutical Research and Development, Titusville, NJ, USA.
  • Podhorna J; Boehringer Ingelheim International GmbH, Ingelheim/Rhein, Germany.
  • Serné E; Department of Internal Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Verbraak F; Department of Ophthalmology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Yaqub M; Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Hillebrand A; Department of Clinical Neurophysiology and MEG Center, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Griffa A; Dutch Connectome Lab, Department of Complex Trait Genetics, Center for Neuroscience and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Pendleton N; Wolfson Molecular Imaging Centre, Division of Neuroscience & Experimental Psychology, University of Manchester, Manchester, UK.
  • Kramer SE; Department of Otolaryngology-Head and Neck Surgery, Section Ear & Hearing, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Teunissen CE; Neurochemistry Laboratory, Department of Clinical chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Lammertsma A; Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Barkhof F; Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • van Berckel BNM; Institutes of Neurology and Healthcare Engineering, University College London, London, UK.
  • Scheltens P; Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Muller M; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, PO Box 7057, 1007, MB, Amsterdam, the Netherlands.
  • Maier AB; Department of Internal Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Herholz K; Department of Medicine and Aged Care, @AgeMelbourne, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
  • Visser PJ; Department of Human Movement Sciences, @AgeAmsterdam, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
BMC Geriatr ; 18(1): 289, 2018 11 26.
Article em En | MEDLINE | ID: mdl-30477432
ABSTRACT

BACKGROUND:

The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study.

METHODS:

The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer's Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid ß and tau in cerebrospinal fluid/blood and neurophysiological measures.

DISCUSSION:

The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration. TRIAL REGISTRATION Nederlands Trial Register NTR5867 . Registered 20 May 2016.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Disfunção Cognitiva / Envelhecimento Saudável Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Disfunção Cognitiva / Envelhecimento Saudável Idioma: En Ano de publicação: 2018 Tipo de documento: Article